secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2026-06-17T16:38:25+00:00
Accession:  0001703057-26-000035
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera announces $56M upfront collaboration with Jazz Pharma for T-cell engager antibodies
--------------------------------------------------------------------------------

- $56M upfront for first two programs; $28M additional upon initiation of third program within 12 months.
- Up to $792M per program in option fees and milestones plus mid-single to low-double-digit royalties on net sales.
- Collaboration targets gastrointestinal cancers and other solid tumors using AbCellera's T-cell engaging multispecific platform.
- Jazz holds exclusive worldwide rights to develop and commercialize after exercising option for each program.
- AbCellera may also conduct IND-enabling studies and manufacture clinical supply for programs under the collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000035/0001703057-26-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000035/abcl-20260617.htm
  HTML page:      https://secwatch.observer/filing/0001703057-26-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer